Paper Details

  1. Home
  2. Paper Details

Rimegepant for the treatment of migraine.

Author: BergerAmnon A, CarrollAustin H, ColonMarc, CornettElyse M, GantiLatha, HasoonJamal, KayeAdam M, KayeAlan D, LiNathan, PaladiniAntonella, RamírezGiovanni F, SongJaehong, VarrassiGiustino, WelschmeyerAlexandra, WinnickAriel

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Migraine is a common headache disorder. While traditional treatments for migraine often focus on acute pain relief and prevention, new drugs targeting CGRP, a key factor in migraine development, are showing promise. Rimegepant, a new CGRP antagonist, has been found to be effective in treating acute migraine attacks and may also be helpful in preventing them.
Paper Details　
Original Abstract of the Article :
Migraine is a common form of primary headache, affecting up to 1 in every 6 Americans. The pathophysiology is an intricate interplay of genetic factors and environmental influence and is still being elucidated in ongoing studies. The trigeminovascular system is now known to have a significant role i...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9560892/

データ提供：米国国立医学図書館（NLM）

Rimegepant: A New Hope in the Desert of Migraine Treatment

Migraine, a debilitating headache disorder, can cast a long shadow over the lives of millions, creating a desert of pain and disruption. This research explores the role of rimegepant, a novel CGRP receptor antagonist, in treating acute migraine attacks. The authors highlight the complex pathophysiology of migraine, emphasizing the involvement of the trigeminovascular system and the release of pain mediators such as CGRP. Traditional migraine treatments, including non-steroidal anti-inflammatory drugs (NSAIDs), triptans, and preventive therapies, often provide limited relief or have significant side effects. Rimegepant, however, has shown promising efficacy in multiple clinical trials, providing rapid relief of migraine symptoms with a favorable safety profile.

A New Oasis in the Desert of Migraine: The Promise of Rimegepant

This research introduces rimegepant as a potential game-changer in the management of acute migraine attacks. The drug's efficacy in reducing migraine symptoms, coupled with its favorable safety profile, suggests that it could offer a new and more effective treatment option for many individuals.

Navigating the Desert of Pain: Finding Relief and Hope

The research on rimegepant offers a beacon of hope for individuals suffering from the debilitating effects of migraine. This novel medication provides a promising new avenue for relief, potentially reducing the burden of migraine attacks and improving quality of life.

Dr.Camel's Conclusion

Rimegepant emerges as a potential oasis in the desert of migraine treatment. This novel CGRP receptor antagonist offers a promising new approach to managing acute migraine attacks, potentially providing more effective relief with a favorable safety profile.

Date :
  1. Date Completed n.d.
  2. Date Revised 2022-10-21
Further Info :

Pubmed ID

36262478

DOI: Digital Object Identifier

PMC9560892

Related Literature

Article Analysis
・Side Effects of rimegepant
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.